Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

CORRECTION — Statera Biopharma Announces Proposed Underwritten Public Offering

Statera Biopharma Announces Proposed Underwritten Public Offering

Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021

Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

CORRECTION – Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera Biopharma Announces Changes to Board of Directors

Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease

Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering